Staff reporter at Bench to Bed, covering Medical Research.
The use of wearable devices to track health metrics is being promoted by health insurance companies and the Department of Health and Human Services, but experts are raising concerns about the potential for increased costs and exploitation of personal data.
Commure, a $7 billion health software company, has terminated its customer referral program that offered payments for promoting its AI tools to new medical clinics. The decision follows a STAT investigation into the company's referral arrangements, which were disclosed in internal emails from Chief Legal Officer Dan Brian.
Health Secretary Robert F. Kennedy Jr. recently visited California to discuss changes to addiction treatment, placing blame on the prior administration for handling the issue.
Novo Nordisk's CEO believes investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will prevent the market from becoming a winner-take-all battle with rival Eli Lilly.
Several pharmaceutical companies have recently made notable appointments and promotions, with Formation Bio hiring a new chief scientific officer and head of research and development.
Both the U.S. and U.K. health systems prioritize clinical interventions over community-based prevention, despite rising chronic illness and loneliness. A shift toward social infrastructure and community empowerment could reduce strain on hospitals and improve public health outcomes.
Luigi Mangione has pleaded guilty to federal stalking charges in the killing of UnitedHealthcare CEO Brian Thompson. Mangione admitted to trailing Thompson to an investor conference and shooting him on a New York City street in 2024.
The U.S. FDA has approved Zenbexus, Bristol Myers Squibb’s oral treatment for advanced multiple myeloma, introducing a new class of blood cancer drugs known as CELMoDs. Meanwhile, a U.S. appeals court revived a $6.7 billion lawsuit accusing Bristol Myers of delaying regulatory approvals for three drugs post-Celgene acquisition.
Valisure accuses USP of making false and misleading remarks about its testing methods, sparking a lawsuit.
The U.S. FDA has approved Bristol Myers Squibb’s oral drug iberdomide, marketed as Zenbexus, for use with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma, marking the first approval of a novel drug class for the disease and the inaugural use of a more sensitive remission endpoint in the United States.
The Federal Trade Commission is examining Epic Systems Corp. for potential violations of antitrust law, focusing on the company's business practices and agreements that may be limiting competition in the electronic health records market.
The American Academy of Pediatrics (AAP) addresses federal leaders' misleading claims about vaccines, reaffirming the safety and importance of childhood immunizations. Pediatricians emphasize evidence-based recommendations, debunk myths, and reassure parents amid growing misinformation.
Pharmacy benefit managers (PBMs) have agreed to display TrumpRx price comparisons, a move that could increase transparency in the pharmaceutical industry.